<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC3184032/results/search/test_trace/results.xml">
  <result pre="as competitive substrates for viral DNA polymerase. Drugs for the" exact="treatment" post="of influenza inhibit the ion channel M2 protein or"/>
  <result pre="neuraminidase. Combination therapy with Interferon-α and ribavirin remains the backbone" exact="treatment" post="for chronic hepatitis C; the addition of serine protease"/>
  <result pre="hepatitis C; the addition of serine protease inhibitors improves the" exact="treatment" post="outcome of patients infected with hepatitis C virus genotype"/>
  <result pre="analogues. Notably, almost all the nucleos(t) ide analogues for the" exact="treatment" post="of chronic hepatitis B possess anti–human immunodeficiency virus properties,"/>
  <result pre="possess multiple potential clinical applications, such as ribavirin for the" exact="treatment" post="of chronic hepatitis C and respiratory syncytial virus and"/>
  <result pre="hepatitis C and respiratory syncytial virus and cidofovir for the" exact="treatment" post="of cytomegalovirus and other DNA viruses. Drug resistance is"/>
  <result pre="the clinical utility of M2 inhibitors for the prevention and" exact="treatment" post="of influenza infections. This article provides an overview of"/>
  <result pre="sections possess other potential applications, such as ribavirin for the" exact="treatment" post="of respiratory syncytial virus (RSV) and cidofovir for the"/>
  <result pre="treatment of respiratory syncytial virus (RSV) and cidofovir for the" exact="treatment" post="of cytomegalovirus (CMV) and other DNA viral infections. Nucleos(t)ide"/>
  <result pre="(CMV) and other DNA viral infections. Nucleos(t)ide analogues for the" exact="treatment" post="of chronic hepatitis B (CHB) may also possess anti-HIV"/>
  <result pre="also possess anti-HIV properties, but their clinical utility for the" exact="treatment" post="of HIV will be discussed in a separate article"/>
  <result pre="in termination of viral replication. Acyclovir is approved for the" exact="treatment" post="of primary and recurrent genital HSV infection (Table 1).2,4,5"/>
  <result pre="approved for the treatment of primary and recurrent genital HSV" exact="infection" post="(Table 1).2,4,5 Topical acyclovir may be used to treat"/>
  <result pre="In immunocompetent individuals, orolabial herpes is often self-limited, and antiviral" exact="treatment" post="is generally not recommended.7 However, oral acyclovir may be"/>
  <result pre="in those who are immunocompromised.7,8 Intravenous acyclovir is the first-line" exact="treatment" post="for HSV encephalitis9 and should be started as soon"/>
  <result pre="imaging of the brain typically demonstrates temporal lobe involvement, and" exact="diagnosis" post="is confirmed by detection of HSV DNA in the"/>
  <result pre="typically demonstrates temporal lobe involvement, and diagnosis is confirmed by" exact="detection" post="of HSV DNA in the CSF. Major studies have"/>
  <result pre="studies have evaluated the efficacy of 10 days of acyclovir" exact="treatment" post="for HSV encephalitis; however, the recommended duration of treatment"/>
  <result pre="acyclovir treatment for HSV encephalitis; however, the recommended duration of" exact="treatment" post="in the clinical setting is 2 to 3 weeks"/>
  <result pre="weeks because shorter durations have been associated with relapse.10 The" exact="treatment" post="duration may be further prolonged in immunocompromised patients.8 Acyclovir"/>
  <result pre="by the US Food and Drug Administration (FDA) for the" exact="treatment" post="of VZV11,12; however, young immunocompetent patients with zoster may"/>
  <result pre="VZV11,12; however, young immunocompetent patients with zoster may not require" exact="treatment" post="if the lesions are localized and have been present"/>
  <result pre="for patients with disseminated zoster disease or visceral involvement. Acyclovir" exact="treatment" post="of zoster reduces duration of viral shedding, formation of"/>
  <result pre="Short-course prednisone may be added as an adjunct to acyclovir" exact="treatment" post="of zoster to improve quality of life, especially in"/>
  <result pre="especially in elderly patients. Acyclovir has been used in the" exact="treatment" post="of acute retinal necrosis (which is associated with HSV"/>
  <result pre="DNA synthesis. It is available in some countries for the" exact="treatment" post="of herpes zoster and herpes simplex. However, concerns about"/>
  <result pre="toxicity.25,26 Cidofovir Cidofovir is a nucleoside analogue used for the" exact="treatment" post="of CMV, other herpesviruses, and other DNA viral infections.27"/>
  <result pre="DNA synthesis.27 The major clinical indication for cidofovir is the" exact="treatment" post="of CMV retinitis in HIV-infected patients (Table 1).31 Cidofovir"/>
  <result pre="DNA polymerase. The major clinical indications for famciclovir use are" exact="treatment" post="of herpes zoster, recurrent genital herpes,52 and recurrent herpes"/>
  <result pre="the risk of recurrent genital herpes as well as oral" exact="treatment" post="of uncomplicated varicella in HIV-infected patients. The most common"/>
  <result pre="synthesis. Fomivirsen is given intravitreally. Its main indication is the" exact="treatment" post="of CMV retinitis in patients with AIDS who have"/>
  <result pre="a nonnucleoside pyrophosphate analogue that is given intravenously for the" exact="treatment" post="of herpesviruses.58 Its pharmacokinetic profile is complicated by a"/>
  <result pre="TK or UL97 kinase mutations.33 Foscarnet is approved for the" exact="treatment" post="of CMV retinitis in patients with AIDS.58 It has"/>
  <result pre="HHV-8 but not against HHV-7.67 Ganciclovir is approved for the" exact="treatment" post="of CMV retinitis in patients with AIDS, the treatment"/>
  <result pre="the treatment of CMV retinitis in patients with AIDS, the" exact="treatment" post="of herpes simplex keratitis, and CMV prophylaxis in transplant"/>
  <result pre="poorly absorbed, oral ganciclovir should not be used for induction" exact="treatment" post="of CMV disease.69 Because CMV disease often recurs or"/>
  <result pre="achieved.69 Intravitreal ganciclovir may also be surgically implanted for the" exact="treatment" post="of CMV retinitis, although this treatment should be used"/>
  <result pre="surgically implanted for the treatment of CMV retinitis, although this" exact="treatment" post="should be used together with systemic therapy with IV"/>
  <result pre="this indication.60,61,70 Intravenous ganciclovir is also used as a first-line" exact="treatment" post="of CMV disease in bone marrow and solid organ"/>
  <result pre="identical to those of acyclovir. It is approved for the" exact="treatment" post="of initial or recurrent episodes of genital herpes76 and"/>
  <result pre="initial or recurrent episodes of genital herpes76 and for the" exact="treatment" post="of recurrent herpes labialis.4 Treatment is most efficacious when"/>
  <result pre="to prevent recurrent genital herpes76 and has the potential to" exact="reduce transmission" post="to sexual partners.4 Valacyclovir is approved for treatment of"/>
  <result pre="to reduce transmission to sexual partners.4 Valacyclovir is approved for" exact="treatment" post="of VZV. Varicella often resolves without antiviral therapy in"/>
  <result pre="uncomplicated.77 Valacyclovir is the most commonly used drug for the" exact="treatment" post="of zoster.75,77 In a randomized double-blind trial of older"/>
  <result pre="lower risk of postherpetic neuralgia.75 The typical course of zoster" exact="treatment" post="is 7 days, and the first dose should be"/>
  <result pre="DNA polymerase. Valganciclovir was first approved by the FDA for" exact="treatment" post="of CMV retinitis in patients with AIDS.83 For immediate"/>
  <result pre="It can also be used to preemptively treat asymptomatic CMV" exact="infection" post="in transplant recipients.85-88 Valganciclovir was recently demonstrated to be"/>
  <result pre="Amantadine is effective as prophylaxis for preventing symptomatic influenza A" exact="infection" post="in exposed persons.92,93 It is usually given for 14"/>
  <result pre="of widespread resistance, amantadine is no longer recommended for empiric" exact="treatment" post="of influenza.94,95 M2 mutation confers cross-resistance with rimantadine. Rimantadine."/>
  <result pre="thereby inhibiting viral uncoating. Rimantadine is indicated for prevention and" exact="treatment" post="of influenza A virus93; however, its clinical utility is"/>
  <result pre="of virus from infected cells.98 Oseltamivir is approved for the" exact="treatment" post="of children (≥1 year) and adults with influenza A"/>
  <result pre="other neuraminidase inhibitor, zanamivir, in reducing the febrile period during" exact="infection" post="with influenza A (H1N1), influenza A (H3N2), and influenza"/>
  <result pre="is an inhaled neuraminidase inhibitor that is used for the" exact="treatment" post="and prophylaxis of influenza A and B viruses.106 Zanamivir"/>
  <result pre="produces high concentrations in the respiratory tract where influenza virus" exact="infection" post="occurs. About 4% to 20% of inhaled zanamivir is"/>
  <result pre="been reported; a bronchodilator should be available if given as" exact="treatment" post="for patients with underlying pulmonary disease. Other adverse effects"/>
  <result pre="chronic viral hepatitis.112 Interferon-α was the first drug approved for" exact="treatment" post="of compensated liver disease due to CHB; it is"/>
  <result pre="therapeutic option. Lamivudine and the other antiviral nucleos(t)ides for the" exact="treatment" post="of HBV often have anti-HIV properties and may result"/>
  <result pre="HBV-HIV coinfected patients. Interferon-α-2a and -2b are approved for the" exact="treatment" post="of chronic hepatitis C (CHC); however, they are not"/>
  <result pre="peginterferon-α combined with oral ribavirin as the first line of" exact="treatment" post="of CHC. The recommended duration of treatment of CHC"/>
  <result pre="first line of treatment of CHC. The recommended duration of" exact="treatment" post="of CHC in patients not infected with HIV is"/>
  <result pre="Interferons are generally not recommended in acute viral hepatitis, but" exact="treatment" post="of acute HCV with IFN-α has resulted in a"/>
  <result pre="peginterferon-α for at least 6 months for acute HCV if" exact="infection" post="persists for 2 to 4 months after diagnosis. Interferons"/>
  <result pre="and those receiving higher doses of IFN-α or undergoing long-term" exact="treatment" post="regimens. Selective serotonin reuptake inhibitors have been used successfully"/>
  <result pre="for use, in combination with IFN-α or peginterferon-α, for the" exact="treatment" post="of CHC. However, it is not effective when given"/>
  <result pre="should be for 48 weeks.150,151 Ribavirin is approved for the" exact="treatment" post="of RSV in children, including hematopoietic stem cell transplant"/>
  <result pre="including hematopoietic stem cell transplant recipients. When used for the" exact="treatment" post="of RSV pneumonia, ribavirin is usually given by the"/>
  <result pre="with good outcomes.153 Ribavirin has been used, off-label, for the" exact="treatment" post="of HSV, influenza, severe acute respiratory syndrome coronavirus,154,155 La"/>
  <result pre="addition to IFN, several nucleos(t)ide analogues are available for the" exact="treatment" post="of CHB (Table 2). With the exception of telbivudine,"/>
  <result pre="properties, it is highly recommended that CHB patients considered for" exact="treatment" post="with these drugs be tested for HIV infection, and"/>
  <result pre="strategy of combination antiviral therapies. The exact duration of anti-HBV" exact="treatment" post="is not defined, and HBV relapse often occurs after"/>
  <result pre="an analogue of cytidine. Although not currently approved for the" exact="treatment" post="of CHB, emtricitabine has been used clinically in combination"/>
  <result pre="is considered one of the most potent agents for the" exact="treatment" post="of patients with CHB, including those resistant to lamivudine.172"/>
  <result pre="synthesis of positive-strand HBV DNA.172 Entecavir is approved for the" exact="treatment" post="of CHB, at a dose of 0.5 mg orally"/>
  <result pre="be used as an alter native to IFN-α for the" exact="treatment" post="of CHB.175,176 In a double-blind study involving about 350"/>
  <result pre="antibody seroconversion, and ALT normalization.177 However, relapses are common once" exact="treatment" post="is discontinued.178 The adverse effects of lamivudine are mild"/>
  <result pre="of viral DNA polymerase. Oral telbivudine is approved for the" exact="treatment" post="of CHB in patients with compensated liver disease and"/>
  <result pre="neuropathy and myopathy with elevation in creatine kinase levels. Telbivudine" exact="treatment" post="should be discontinued if either peripheral neuropathy or myopathy"/>
  <result pre="into the viral DNA strand. Tenofovir is used for the" exact="treatment" post="of CHB. In a randomized trial comparing tenofovir and"/>
  <result pre="Protease Inhibitors for the Treatment of CHC The current standard" exact="treatment" post="of CHC is peginterferon-α in combination with ribavirin for"/>
  <result pre="48 weeks (for HCV genotype 1). The major aim of" exact="treatment" post="is to achieve SVR, which is defined as undetectable"/>
  <result pre="ketoamide serine protease inhibitor that was recently approved for the" exact="treatment" post="of CHC, particularly for genotype 1.194 It is available"/>
  <result pre="previously untreated black and nonblack adults with HCV genotype 1" exact="infection" post="(SPRINT-2 [serine protease inhibitor therapy 2] trial), the addition"/>
  <result pre="Inhibitor Boceprevir and PegIntron/Rebetol 2) trial evaluated boceprevir for the" exact="treatment" post="of patients who had experienced a relapse or who"/>
  <result pre="were significantly higher for patients who received peginterferon-ribavirin plus boceprevir" exact="treatment" post="for 32 weeks (59%) or 44 weeks (66%) compared"/>
  <result pre="weeks (59%) or 44 weeks (66%) compared with standard peginterferon-ribavirin" exact="treatment" post="alone (21%).196 In a multivariable stepwise logistic regression analysis,"/>
  <result pre="the FDA as the first HCV protease inhibitor for the" exact="treatment" post="of CHC, specifically for genotype 1; it should be"/>
  <result pre="placebo-controlled clinical trial, the addition of telaprevir to the standard" exact="treatment" post="of peginterferon-ribavirin was associated with significantly higher SVR rates"/>
  <result pre="genotype 1 infection, the addition of telaprevir to the standard" exact="treatment" post="regimen of peginterferon-α and ribavirin was associated with significantly"/>
  <result pre="1 and in those who did not benefit from initial" exact="treatment" post="with peginterferon-α-2a and ribavirin. As a result of these"/>
  <result pre="FDA approved telaprevir (750 mg 3 times daily) for this" exact="treatment" post="indication. The most common adverse effects are anemia, neutropenia,"/>
  <result pre="resistance has been observed to the neuraminidase inhibitors for the" exact="treatment" post="of influenza viruses and the nucleos(t)ide analogues for the"/>
  <result pre="treatment of influenza viruses and the nucleos(t)ide analogues for the" exact="treatment" post="of CHB. As novel therapies develop (eg, the serine"/>
  <result pre="novel therapies develop (eg, the serine protease inhibitors for the" exact="treatment" post="of CHC), care must be taken to optimize their"/>
  <result pre="to (1) discuss the different regimens for the prevention and" exact="treatment" post="of human herpesviruses; (2) discuss options for the prevention"/>
  <result pre="of human herpesviruses; (2) discuss options for the prevention and" exact="treatment" post="of influenza virus, including infections with resistant strains; and"/>
  <result pre="with resistant strains; and (3) discuss antiviral drugs for the" exact="treatment" post="of chronic hepatitis B and C infections, including novel"/>
  <result pre="protease inhibitors, respectively. References REFERENCES 1.CoreyLFifeKHBenedettiJKet al.Intravenous acyclovir for the" exact="treatment" post="of primary genital herpes. Ann Intern Med. 1983;98:914-9216305244 2.NilsenAEAasenTHalsosAMet"/>
  <result pre="Intern Med. 1983;98:914-9216305244 2.NilsenAEAasenTHalsosAMet al.Efficacy of oral acyclovir in the" exact="treatment" post="of initial and recurrent genital herpes. Lancet. 1982;2:571-5736125728 3.SerotaFTStarrSEBryanCKKochPAPlotkinSAAugustCSAcyclovir"/>
  <result pre="treatment of initial and recurrent genital herpes. Lancet. 1982;2:571-5736125728 3.SerotaFTStarrSEBryanCKKochPAPlotkinSAAugustCSAcyclovir" exact="treatment" post="of herpes zoster infections: use in children undergoing bone"/>
  <result pre="controlled trial. JAMA. 1984;251:2103-21076368877 6.LubyJPGnannJWJrAlexanderWJet al.A collaborative study of patient-initiated" exact="treatment" post="of recurrent genital herpes with topical acyclovir or placebo."/>
  <result pre="with topical acyclovir or placebo. J Infect Dis. 1984;150:1-66086765 7.CernikCGallinaKBrodellRTThe" exact="treatment" post="of herpes simplex infections: an evidence-based review. Arch Intern"/>
  <result pre="recipients. Am J Transplant. 2009;9(suppl 4):S104-S10720070669 9.De ClercqEAntivirals for the" exact="treatment" post="of herpesvirus infections. J Antimicrob Chemother. 1993;32(suppl A):121-1328407694 10.ValenciaIMilesDKMelvinJet"/>
  <result pre="cases and review of the literature. Neuropediatrics. 2004;35:371-37615627947 11.BalfourHHJrKellyJMSuarezCSet al.Acyclovir" exact="treatment" post="of varicella in otherwise healthy children. J Pediatr. 1990;116:633-6392156984"/>
  <result pre="neurotoxicity. Ann Pharmacother. 1998;32:111-1139475829 19.WadeJCMeyersJDNeurologic symptoms associated with parenteral acyclovir" exact="treatment" post="after marrow transplantation. Ann Intern Med. 1983;98:921-9256305245 20.BuckMLVittoneSBZaglulHFVesicular eruptions"/>
  <result pre="and development of BVDU (brivudin) as a therapeutic for the" exact="treatment" post="of herpes zoster. Biochem Pharmacol. 2004;68:2301-231515548377 27.LeaAPBrysonHMCidofovir. Drugs. 1996;52:225-2308841740"/>
  <result pre="2004;68:2301-231515548377 27.LeaAPBrysonHMCidofovir. Drugs. 1996;52:225-2308841740 28.LanierRTrostLTippinTet al.Development of CMX001 for the" exact="treatment" post="of poxvirus infections. Viruses. 2010;2:2740-276221499452 29.WolfDLRodriguezCAMucciMIngrossoADuncanBANickensDJPharmacokinetics and renal effects"/>
  <result pre="analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36:127-14310092959 31.KendleJBFan-HavardPCidofovir in the" exact="treatment" post="of cytomegaloviral disease. Ann Pharmacother. 1998;32:1181-11929825085 32.CherringtonJMFullerMDLamyPDet al.In vitro"/>
  <result pre="Antimicrob Agents Chemother. 1998;42:2240-22449736542 34.SnoeckRDe ClercqERole of cidofovir in the" exact="treatment" post="of DNA virus infections, other than CMV infections, in"/>
  <result pre="the literature. Transpl Infect Dis. 2005;7:158-16116390407 36.LamothFPascualMErardVVenetzJPNseirGMeylanPLow-dose cidofovir for the" exact="treatment" post="of polyomavirus-associated nephropathy: two case reports and review of"/>
  <result pre="of the literature. Antivir Ther. 2008;13:1001-100919195325 37.ToroJRSanchezSTurianskyGBlauveltATopical cidofovir for the" exact="treatment" post="of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex"/>
  <result pre="Clin. 2003;21:301-30912757253 38.LalezariJPDrewWLGlutzerEet al.Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous" exact="infection" post="with herpes simplex virus in a patient with AIDS."/>
  <result pre="in a patient with AIDS. J Infect Dis. 1994;170:570-5728077713 39.BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful" exact="treatment" post="of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in"/>
  <result pre="cidofovir in a child. Pediatr Infect Dis J. 2001;20:1083-108611734717 40.KoppTGeusauARiegerAStinglGSuccessful" exact="treatment" post="of an aciclovir-resistant herpes simplex type 2 infection with"/>
  <result pre="2001;20:1083-108611734717 40.KoppTGeusauARiegerAStinglGSuccessful treatment of an aciclovir-resistant herpes simplex type 2" exact="infection" post="with cidofovir in an AIDS patient. Br J Dermatol."/>
  <result pre="cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16:1791-179712218391 43.RazonableRRAksamitAJWrightAJWilsonJWCidofovir" exact="treatment" post="of progressive multifocal leukoencephalopathy in a patient receiving highly"/>
  <result pre="Study GroupA randomized controlled clinical trial of intravitreous fomivirsen for" exact="treatment" post="of newly diagnosed peripheral cytomegalovirus retinitis in patients with"/>
  <result pre="Biol Chem. 1984;259:1566-15696319402 67.RazonableRRPayaCVThe impact of human herpesvirus-6 and -7" exact="infection" post="on the outcome of liver transplantation. Liver Transpl. 2002;8:651-65812149755"/>
  <result pre="collab: Syntex Cooperative Oral Ganciclovir Study GroupOral ganciclovir as maintenance" exact="treatment" post="for cytomegalovirus retinitis in patients with AIDS. N Engl"/>
  <result pre="and outcomes. Clin Transplant. 2008;22:162-17018339135 72.SariskyRTBaconTHBoonRJet al.Profiling penciclovir susceptibility and" exact="prevalence" post="of resistance of herpes simplex virus isolates across eleven"/>
  <result pre="74.SpruanceSLReaTLThomingCTuckerRSaltzmanRBoonR; collab: Topical Penciclovir Collaborative Study GroupPenciclovir cream for the" exact="treatment" post="of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled"/>
  <result pre="GroupA large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic" exact="treatment" post="of recurrent herpes genitalis. Arch Intern Med. 1996;156:1729-17358694673 77.PergamSALimayeAPVaricella"/>
  <result pre="N Engl J Med. 1999;340:1462-147010320384 79.RazonableRRPayaCVValganciclovir for the prevention and" exact="treatment" post="of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti"/>
  <result pre="al.Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus" exact="infection" post="in adult renal transplant recipients. Am J Transplant. 2006;6:2134-214316780548"/>
  <result pre="Am J Transplant. 2006;6:2134-214316780548 86.SnydmanDRUse of valganciclovir for prevention and" exact="treatment" post="of cytomegalovirus disease [editorial]. Clin Infect Dis. 2008;46:28-2918171209 87.EinseleHReusserPBornhauserMet"/>
  <result pre="following allogeneic stem cell transplantation. Blood. 2006;107:3002-300816352807 88.LenOGavaldaJAguadoJMet al.Valganciclovir as" exact="treatment" post="for cytomegalovirus disease in solid organ transplant recipients. Clin"/>
  <result pre="89.AsbergAHumarARollagHet al.Oral valganciclovir is noninferior to intravenous ganciclovir for the" exact="treatment" post="of cytomegalovirus disease in solid organ transplant recipients. Am"/>
  <result pre="prevention of influenza A. Semin Respir Infect. 1989;4:304-3102697053 94.KrumbholzASchmidtkeMBergmannSet al.High" exact="prevalence" post="of amantadine resistance among circulating European porcine influenza A"/>
  <result pre="the clinical effectiveness of oseltamivir and zanamivir against influenza virus" exact="infection" post="in children. Clin Infect Dis. 2008;47:339-34518582202 100.KhazeniNBravataDMHoltyJEUyekiTMStaveCDGouldMKSystematic review: safety"/>
  <result pre="oseltamivir: descriptive study. Lancet. 2004;364:759-76515337401 102.de JongMDTranTTTruongHKet al.Oseltamivir resistance during" exact="treatment" post="of influenza A (H5N1) infection. N Engl J Med."/>
  <result pre="(H5N1) infection. N Engl J Med. 2005;353:2667-267216371632 103.LeQMKisoMSomeyaKet al.Avian flu:" exact="isolation" post="of drug-resistant H5N1 virus. Nature. 2005;437:110816228009 104.DharanNJGubarevaLVMeyerJJet al.Infections with"/>
  <result pre="pharmacokinetic properties. Semin Liver Dis. 2003;23(suppl 1):19-2212934164 112.WongDKCheungAMO’RourkeKNaylorCDDetskyASHeathcoteJEffect of alpha-interferon" exact="treatment" post="in patients with hepatitis B e antigen-positive chronic hepatitis"/>
  <result pre="al.Short statement of the first European Consensus Conference on the" exact="treatment" post="of chronic hepatitis B and C in HIV co-infected"/>
  <result pre="Hepatol. 2005;42:615-62415916745 123.PoynardTLeroyVCohardMet al.Meta-analysis of interferon randomized trials in the" exact="treatment" post="of viral hepatitis C: effects of dose and duration."/>
  <result pre="plus ribavirin compared with interferon alfa-2b plus ribavirin for initial" exact="treatment" post="of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-96511583749"/>
  <result pre="hepatitis C: a randomised trial. Lancet. 2001;358:958-96511583749 130.GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and" exact="treatment" post="of hepatitis C: an update. Hepatology. 2009;49:1335-137419330875 131.CarratFBani-SadrFPolSet al.Pegylated"/>
  <result pre="132.TorrianiFJRodriguez-TorresMRockstrohJKet al.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus" exact="infection" post="in HIV-infected patients. N Engl J Med. 2004;351:438-45015282351 133.ChungRTAndersenJVolberdingPet"/>
  <result pre="acuminata. N Engl J Med. 1986;315:1059-10643531860 137.LeungDTSacksSLCurrent recommendations for the" exact="treatment" post="of genital herpes. Drugs. 2000;60:1329-135211152015 138.HuangSSSkolaskyRLDal PanGJRoyalWIIIMcArthurJCSurvival prolongation in"/>
  <result pre="and review of the literature. Clin Infect Dis. 2004;39:1724-172915578378 143.LevensonJLFallonHJFluoxetine" exact="treatment" post="of depression caused by interferon-alpha. Am J Gastroenterol. 1993;88:760-7618480744"/>
  <result pre="virus. Am J Gastroenterol. 2009;104:2335-234119513022 152.VentreKRandolphAGRibavirin for respiratory syncytial virus" exact="infection" post="of the lower respiratory tract in infants and young"/>
  <result pre="al.Treatment of severe La Crosse encephalitis with intravenous ribavirin following" exact="diagnosis" post="by brain biopsy. Pediatrics. 1997;99:261-2679024460 157.ChongHTKamarulzamanATanCTet al.Treatment of acute"/>
  <result pre="ribavirin. Lancet. 1995;346:472-4757637481 161.MardaniMJahromiMKNaieniKHZeinaliMThe efficacy of oral ribavirin in the" exact="treatment" post="of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis."/>
  <result pre="in chronic hepatitis B. Drugs. 2003;63:2215-223414498759 165.RivkinAMAdefovir dipivoxil in the" exact="treatment" post="of chronic hepatitis B. Ann Pharmacother. 2004;38:625-63314990784 166.MarcellinPChangTTLimSGet al.Adefovir"/>
  <result pre="hepatitis B. Ann Pharmacother. 2004;38:625-63314990784 166.MarcellinPChangTTLimSGet al.Adefovir dipivoxil for the" exact="treatment" post="of hepatitis B e antigen-positive chronic hepatitis B. N"/>
  <result pre="N Engl J Med. 2003;348:808-81612606735 167.HadziyannisSJTassopoulosNCHeathcoteEJet al.Adefovir dipivoxil for the" exact="treatment" post="of hepatitis B e antigen-negative chronic hepatitis B. N"/>
  <result pre="hepatitis B. N Engl J Med. 2005;352:2673-268115987916 169.DelaneyWEProgress in the" exact="treatment" post="of chronic hepatitis B: long-term experience with adefovir dipivoxil."/>
  <result pre="Intern Med. 2006;166:49-5616401810 171.SimsKAWoodlandAMEntecavir: a new nucleoside analog for the" exact="treatment" post="of chronic hepatitis B infection. Pharmacotherapy. 2006;26:1745-175717125436 172.MatthewsSJEntecavir for"/>
  <result pre="of chronic hepatitis B infection. Pharmacotherapy. 2006;26:1745-175717125436 172.MatthewsSJEntecavir for the" exact="treatment" post="of chronic hepatitis B virus infection. Clin Ther. 2006;28:184-20316678641"/>
  <result pre="infection. N Engl J Med. 1995;333:1657-16617477217 176.DienstagJLSchiffERWrightTLet al.Lamivudine as initial" exact="treatment" post="for chronic hepatitis B in the United States. N"/>
  <result pre="Clin Infect Dis. 2006;42:283-29016355343 194.FooteBCSpoonerLMBelliveauPPBoceprevir: a protease inhibitor for the" exact="treatment" post="of chronic hepatitis C [Epub ahead of print August"/>
 </snippets>
</snippetsTree>
